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500 000 new cases of lung cancer are diagnosed world-wide
annually. 80% of these are non-small-cell type (NSCLC). Pleural
mesothelioma is a less common cancer arising from the serosa of
the lung, the incidence of which is closely linked to asbestos
exposure. The response rates to conventional chemotherapy for
both these cancers ranges from 20% to 50%. Chemotherapy gives
symptom palliation and improvement in quality of life for patients
with these tumours and a small but real and reproducible improve-
ment in survival for NSCLC tumours (Ellis et al, 1995). Over the
last 10 years, many new drugs with novel mechanisms of action
have shown activity against lung cancer, but the survival rates are
comparable to established agents (Webb and O’Brien, 1998). There
remains therefore a need for new strategies, one of which is the re-
exploration of immunotherapy. Therapeutic vaccination using non-
specific immunostimulants, e.g. intradermal BCG, has been tested
in randomized clinical trials in lung cancer, but a clear benefit has
never been shown for its use (Al-Moundhri et al, 1998).
The hypothesis leading to this study was that chemotherapeutic
agents could induce in vivo release of either tumour-specific or
tumour-associated antigens from the treated tumour and that a
non-specific immunostimulator could concomitantly boost tumour
antigen recognition in patients who may be immuno-suppressed
from their cancer. SRL172 is a suspension of heat-killed
Mycobacterium vaccae which is currently undergoing clinical
evaluation in humans. Immunological effects have been observed
in patients with prostate cancer and melanoma (Hrouda et al, 1998;
Maraveyas et al, 1999). Randomized phase II trials to study the
clinical and immunological effects of SRL172 in patients with
cancer have been carried out at the Royal Marsden Hospital, with
a view to developing it as an immunological adjuvant for tumour
treatments. In this study, the feasibility, toxicity and clinical effects
of combining intradermal SRL172 with intravenous chemotherapy
were assessed in a cohort of patients presenting with advanced,
inoperable lung cancer or mesothelioma.
PATIENTS AND METHODS
29 previously untreated patients with histologically or cytologically
verified symptomatic NSCLC, or mesothelioma, were randomized
to receive either intradermal SRL172 given concurrently with
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SRL172 appeared to improve sleep (P = 0.08) and improved appetite (P = 0.01). There was no detectable change in serum cytokine levels
for gamma-interferon and TNF-a before and after treatment. In patients with NSCLC and mesothelioma, there may be a beneficial interaction
when chemotherapy is administered in combination with SRL172. Confirmation of this effect and further investigation is underway in a
randomized phase III trial and in laboratory models. © 2000 Cancer Research Campaign
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This was the NSCLC part of a larger phase II study using the same
design for SCLC comparing chemotherapy to chemotherapy with
SRL 172 (28 patients), and in asymptomatic patients with NSCLC
and mesothelioma comparing best supportive care (BSC) to BSC
with injections of SRL 172 (28 patients). The latter 2 components
of this trial will be reported within the next 12–18 months. All
patients had lesions evaluable by clinical or radiological examina-
tion. Other inclusion criteria were life-expectancy of 12 weeks or
more, age over 18 years and satisfactory renal function. Patients
whose performance status was 3 or more, or who had serious
concomitant illness were excluded. The protocol was approved by
the Research Ethics Committees of The Royal Marsden NHS Trust
and the Kent Cancer Centre. Written informed consent was
obtained from all patients. All patients underwent pre-treatment
physical examination, plasma electrolytes, urea and creatinine,
serum liver function tests, chest radiography and staging of disease
with a thoraco-abdominal CT scan. Clinical assessment of symp-
toms took place at the time of randomization, monthly while
receiving injections of SRL172 and thereafter at 3–6 monthly
intervals. Quality of life data collection was planned at baseline
and at 3 monthly intervals, patients were in addition asked specifi-
cally in one question if their sleep pattern had changed and if their
appetite had changed. At each assessment visit, patients had phys-
ical examination, FBC and chest radiography. Objective response
was measured by CT scanning every two courses.
15 patients received standard combination chemotherapy alone
(mitomycin C 8 mg/m2 on course 1, 2, 4 and 6, vinblastine 6 mg/
m2 (maximum dose 10 mg) and cisplatin 50 mg/m2) and 14
patients received the same chemotherapy combined with SRL172.
Chemotherapy was given at 3 weekly intervals for a maximum of
6 courses and SRL172 was given intradermally prior to the first
chemotherapy and then at monthly intervals for the first 3 injec-
tions, then at 3–6 monthly intervals thereafter. Antiemetics were
routinely prescribed but dexamethasone was omitted for the first
course in those who received SRL172.
SRL172 was formulated as a suspension of 10 mg/ml heat killed
Mycobacterium vaccae in borate buffered saline (pH 8) and
provided in 3 ml glass vials at a concentration of 109 bacilli per
0.1 ml dose and stored refrigerated at 4°C in the pharmacies of
both hospitals taking part in the trial.
Serum cytokine levels of TNF-alpha, gamma-interferon and IL-
10 were measured by ELISA pre- and post-treatment (1 month
after the end of the chemotherapy) using the supplier protocol
(R&D Systems, Abingdon, UK).
RESULTS
Patient characteristics are shown in Table 1. The two groups were
well balanced with regard to performance status, age and sex, but
there were slightly more patients with adenocarcinoma in the
chemotherapy alone group (2 versus 5). One patient in the
combined treatment arm was not eligible for entry into the study
because of the presence of renal failure and ongoing immunosup-
pressive therapy prior to treatment.
There were 20 male and 9 female patients. WHO performance
status (PS) was as follows; 9 patients were PS 1, 19 patients were
PS 2, 1 patient was PS 3. A total of 9 patients had mesothelioma
and 20 had NSCLC. The majority of patients were stage IIIB or
stage IV, with 2 patients stage IIIA. The median age was 60 years
(range 33–71 years).
At the time of randomization, all patients had symptoms
requiring treatment. These consisted of cough, dyspnoea and/or
pain. Following injection of SRL172, there was no treatment
related toxicity, except for some induration at the injection site. In
the group treated with chemotherapy plus SRL172, on the inten-
tion to treat analysis (ITT) there was a trend towards an improved
median survival was 9.4 months vs 7.5 months (P = 0.3), and
looking at the patients evaluable for response (n = 28) there was
also a trend towards improved response rate (54% vs. 33%, P =
0.3), improved median survival (9.7 months vs. 7.5 months, P =
0.235) and in the proportion of treated patients alive at one year
(42% vs. 18%) compared with the group receiving chemotherapy
alone (Figure 1: intention to treat survival analysis). Two patients
in the combined treatment arm subsequently underwent potentially
curative surgery and one patient had radical radiotherapy.
Treatment toxicity is shown in Tables 2 and 3 and was compa-
rable in the two groups of patients. SRL172 appeared to improve
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Table 1 Patient characteristics
Chemotherapy + SRL172 Chemotherapy
Sex F/M 3/11 6/9
Age 61 59
Range 33–71 40–70
PS 1 3 6
21 0 9
31 0
Stage IIIa 1 1
IIIb 7 6
IV 6 8
Path adeno 2 5
squamous 2 2
adenosquamous 1 0
large cell 0 1
unclassified 5 2
mesothelioma 4 5
No previous radiotherapy 12 14
Weight loss in past 3 mths
< 5% 11 10
5+% 3 5sleep (P = 0.08) and improved poor appetite (P = 0.01). Full
quality of life assessment has not been analysed as the numbers
of patients returning repeat questionnaires was small. There was
one treatment related death in the group receiving SRL172 and
chemotherapy. A patient with Poland’s syndrome (congenital
absence of the chest wall) with a stage IV adenocarcinoma devel-
oped a chest infection after 4 courses of chemotherapy. Initially
he was neutropenic but this quickly resolved. His disease was
responding on assessment of the measurable mass on his sternum.
The lung cancer was on the R side – the side of this absent chest
wall, the infection was mostly on this side also. We felt the cause
of death was a chest infection in this hypoventilated lung but
underlying progressive disease could have contributed. Permission
to do a post-mortem was not given after his death. Of the patients
with mesothelioma, 2/4 had PR in the combination group
compared with 1/5 in the chemotherapy alone group.
Serum cytokine levels of TNF-a, g-interferon (g-IFN) and IL-10
were measured by ELISA (R&D systems) pre- and post-treatment
at 1 month after the end of the chemotherapy (Table 4). There was
no statistical difference between the 2 treatment groups
(chemotherapy and chemotherapy + SRL 172) at baseline for the
g-IFN and TFN-a serum levels (P = 0.2 and P = 0.9 respectively,
two-tailed P value, Mann-Whitney U-test). Baseline levels were
also compared between responders and non-responders irrespec-
tive of the treatment group as possible prognostic factors. There
was no difference in the serum levels of g-IFN (P = 0.76, Mann-
Whitney U test, 2 tailed P value) but the serum levels of TNF-a at
baseline were lower in the responders group (mean 37.9 pg/ml)
compared to the non-responders group (mean 45.8 pg/ml), (P =
0.01, two-tailed P value, Mann-Whitney U-test). However the
P value became non-significant when it was corrected for the
number of comparisons done in the study (´ 14) using the
Bonferoni correction: P = 0.14. In addition there was no differ-
ence, when baseline cytokine levels were compared to post-treat-
ment levels (P values are shown in the last column of Table 3).
IL-10 was detected in the serum of only 30% of patients (the IL-10
serum levels of the rest of the patients were too low for the sensi-
tivity of the assay which was 39 ng/ml in-house). There was no
obvious correlation with response both at baseline or post-
treatment.
DISCUSSION
The results of this randomized phase II study suggest a benefit by
combining intravenous chemotherapy with intradermal injection
of SRL172, heat-killed Mycobacterium vaccae, in patients with
lung cancer. Combining cytotoxic drugs with immune-modulators
is not a new concept (Mitchell, 1992) but there have been concerns
that negative interactions might take place due to the myelo-
suppressive properties of many cytotoxic drugs. Cytotoxic drugs
also preferentially kill cells in division, a hallmark of an activated
immune system, and therefore could inhibit immune responses.
However, the particular combination of cytotoxic drugs used in
this study is not very myelo-suppressive at the doses prescribed in
lung cancer patients and therefore the mycobacterium was given
with the chemotherapy.
The cytotoxic drugs were administered according to the
standard protocol at 3 weekly intervals, whereas we decided
empirically to follow a monthly schedule with the Mycobacterium
vaccae because of previous vaccination protocols with SRL172
designed for patients with melanoma, prostate cancer, tuberculosis
and AIDS. Thus, one intradermal SRL172 injection was given
concommitantly with the chemotherapy, the second boost was
given one week after chemotherapy and the third was given 2
weeks after the chemotherapeutic drugs. Theoretically, the timing
of the SRL172 injection in relation to the administration of
chemotherapy may be relevant to any cytotoxic effects.
Chemotherapeutic agents usually induce myelosuppression with a
decrease in white blood cell count after 2 to 7 days with a rebound
between 1 to 2 weeks. Thus the first 3 injections of SRL172 corre-
sponded to different points in the chemotherapy cycle. The first
injection was just before chemotherapy covering the time when
early apoptosis may have been induced by chemotherapy (24
hours) (Ellis et al, 1997). The second injection (day 7 post
SRL172 combined with chemotherapy in lung cancer 855
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Figure 1. Survival analysis (intention to treat)
Table 2 Haematological toxicity (% of cycles at any time during study
period)
Chemotherapy + SRL172 Chemotherapy
n = 50 n = 57
Haemaglobin
Abnormal 74% 65%
G3,4 0% 0%
Neutrophils
Abnormal 6% 21%
G3,4 2% 2%
Lymphocytes
Abnormal 52% 56%
Platelets
Abnormal 14% 33%
G3,4 0 0
Table 3 Non-haematological toxicity (Grade 3, 4 total number on any cycle)
Chemotherapy +SRL172 Chemotherapy
Infection 3* 0
Nausea and vomiting 5 1
Mucositis 0 0
Diarrhoea 0 0
Constipation 0 0
Alopecia 2 0
Nephrotoxicity 1 1
Malaise 2 3
Poor appetite 2 13 (P = 0.01)
Insomnia 5 14 (P = 0.08)
* One toxic deathchemotherapy) may have corresponded to the time where antigen
shedding from the tumour took place and the third injection (day
15 post chemotherapy) should have covered the period of bone
marrow and lymphocyte recovery.
Other workers have suggested that SRL172 may be a non-
specific immunomodulator and that it may promote a predomi-
nantly Th1 type (cell-mediated) response (Grange et al, 1995). For
example, in a study of 10 patients with advanced prostate cancer
who were treated with SRL172 alone, PSA levels were found to
decrease in 2 out of 10 patients as a result of treatment (Hrouda et
al, 1998). The response in these patients correlated with increased
intracellular IL-2 production in lymphocytes, a finding reported
by the same group to occur in advanced melanoma patients
(Maraveyas et al, 1999). However, the mechanism of the possible
anti-tumour effect is unclear. It has been reported that patients with
malignant disease have defective Th1 cell function in association
with elevated Th2 cell levels (Pellegrine et al, 1996); thus a change
in the balance towards improved Th1 function may be of critical
importance to the success of immunotherapy in cancer.
In the present study, we measured serum cytokines only. Serum
cytokines levels of gamma-IFN and TNF-a were not different
between the two treatment groups indicating that there was no bias
of selection for these cytokine levels. However, there was a lower
TNF-a serum level in the responders compared to the non-respon-
ders and at present we do not know if this could have prognostic
significance. There was no correlation with response although
serum cytokine changes could have been missed because of the
timing of the assay or the lack of sensitivity of the assay as in the
case of IL-10. We have just completed a subsequent study in
mesothelioma patients treated with chemotherapy and SRL172.
We found that the patients who responded to treatment had
decreased level of IL-4 producing T lymphocytes and activation of
natural killer (NK) cells (assessed by CD69 expression) with
concomitant increase in NK cell number (BES, in preparation).
However, we did not find an increase of IL-2-producing T cells in
the responder patients. At this stage, we do not know if the
immunological changes contributed to or were a consequence of
tumour regression, or if they were simply due to SRL172 injection
with no role in the anti-tumour process or, even, due to
chemotherapy alone. Therefore the mode of action of SRL172 is
still under investigation in our laboratory.
Reports of possible synergy between chemotherapy and
immunotherapy date back to the early 1980s when the work of
Hanna and Key demonstrated increased survival in guinea pigs
bearing syngeneic L10 hepatocarcinoma cells when cytotoxic
drugs were administered at the peak of the inflammatory response
following tumour vaccination. They hypothesized that drug cyto-
toxicity was enhanced in the tumour if tumour architecture was
disrupted by the inflammatory reaction, allowing better access of
the drugs into the tumour (Hanna and Key, 1982). Another possi-
bility is that SRL172 may possess some true vaccine properties,
and may express cross-reactive antigens with cancer cells.
Obvious candidates for such cross-reactive antigens are heat-
shock proteins (hsp) which are highly conserved across species;
thus mycobacterial hsp are likely to show homology with those
known to be present on human tumour cells. Some hsps are highly
expressed in cancer cells compared with normal cells (Ferrarini et
al, 1992) and it might be anticipated that the hsp expression levels
would increase after treatment with chemotherapy. This possibility
is at present under investigation in our laboratory.
This study encouraged a large phase III randomized trial to test
the hypothesis that there may indeed be a clinical interaction
between SRL172 and combination chemotherapy in patients with
non-small-cell lung cancer. Such a trial is now underway with a
recruitment of 418 patients completed.
ACKNOWLEDGEMENTS
We are grateful to SR Pharma plc for support.
REFERENCES
Al-Moundhri M, O’Brien M and Souberbielle BE (1998) Immunotherapy and lung
cancer. Br J Cancer 78: 282–288
Ellis PA, Smith IE and Hardy JR (1995) Symptom relief with MVP (mitomycin C,
vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung
cancer. Br J Cancer 71: 366–370
Ellis PA, Smith IE, McCarthy K, Detre S, Salter J and Dowsett M (1997)
Preoperative chemotherapy induces apoptosis in realy breast cancer. Lancet
349: 849
Ferrarini M, Heltai S, Zocchi MR and Rugarli C (1992) Unusual expression of and
localisation heat-shock proteins in human tumour cells. Int J Cancer 51:
613–619
856 MER O’Brien et al
British Journal of Cancer (2000) 83(7), 853–857 © 2000 Cancer Research Campaign
Table 4 Serum cytokine levels at baseline and post-treatment
Cytokine Response to treatment Baseline Post-treatment P value*
(mean) (1 month)
Resp Chemo 4.5 (< 1–13.6) 1.9 (< 1–5.9) 0.9
Chemo + SRL172 4.1 (< 1–11.7) 1.0 (< 1–2.3) 0.3
g-INF 4.2 1.32 0.15
(pg/ml)
N.Resp Chemo 13.3 (< 1–30.3) 3.5 (< 1–12.1) 0.1
Chemo + SRL172 1.3 (< 1–5.3) 0.7 (< 1–2.65) 0.99
8.5 2.3 0.1
Resp Chemo 39.1 (33.2–45.7) 38.6 (36.8–39.5) 0.99
Chemo + SRL172 37.2 (33.9–41.4) 42.8 (38.8–51.2) 0.18
TNF-a 37.9 41.2 0.3
(pg/ml)
N.Resp Chemo 43.6 (31.9–50.2) 45.4 (35.9–57.4) 0.56
Chemo + SRL172 49.1 (39.5–60.6) 43.9 (28–50.7) 0.62
45.8 44.8 0.9
The mean values for all responders (Resp) and non responders, (N.Resp) irrespective of the treatment are also shown for both
cytokines (third, sixth, ninth and last line). *Paired Wilcoxon signed rank test.Grange JM, Stanford JL and Rook GAW (1995) Tuberculosis and cancer: parallels
in host responses and therapeutic approaches? Lancet 345: 1350–1352
Hanna MG and Key ME (1982) Immunotherapy of metastases enhances subsequent
chemotherapy. Science 217: 367–369
Hrouda D, Baban B, Dunsmuir WD, Kirby RS and Dalgleish AG (1998)
Immunotherapy of advanced prostate cancer: a phase I/II trial using
Mycobacterium vaccae (SRL172). Br J Urol 82: 568–573
Maraveyas A, Baban B, Kennard D, Rook GAW, Westby M, Grange JM, Lydiard P,
Stanford JL, Jones M, Selby P and Dalgleish AGD (1999). Possible improved
survival of patients with stage IV AJCC melanoma receiving SRL172
immunotherapy: correlation with induction of increased levels of intracellular
interleukin-2 in peripheral blood lymphocytes. Ann Oncol 10: 817–824
Mitchell MS (1992) Chemotherapy in combination with biomodulation: a 5 year
experience with cyclophosphamide and IL-2. Semin Oncol 19 (supp 2): 80–87
Pellegrine P, Berhelia AM and Del Beato T (1996) Dysregulation of Th1 and Th2
subsets of CD4+ cells in peripheral blood of colorectal patients and
involvement in cancer establishment and progression. Cancer Immunol
Immunother 42: 1–8
Webb A and O’Brien MER (1998) Where do we go with new expensive treatments
in NSCLC? Br J Cancer 78(2): 159–162
SRL172 combined with chemotherapy in lung cancer 857
British Journal of Cancer (2000) 83(7), 853–857 © 2000 Cancer Research Campaign